In this context, PARPi can amplify the benefit deriving from ICIs, throughout their above-described effects including preferential generation of a Th1 immune response via the cGAS-STING/type I IFN signaling, better activation of APC cells, improved intra-tumor enrolment of CD8+ cytotoxic T cells and increased PD-L1 expression on tumor cells [87,119,280]. Here, STING1 is linked to neoplasm.